16,216 reports of this reaction
7.8% of all METOCLOPRAMIDE HYDROCHLORIDE reports
#1 most reported adverse reaction
TARDIVE DYSKINESIA is the #1 most commonly reported adverse reaction for METOCLOPRAMIDE HYDROCHLORIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 16,216 FDA adverse event reports linking METOCLOPRAMIDE HYDROCHLORIDE to TARDIVE DYSKINESIA. This represents approximately 7.8% of all 206,778 adverse event reports for this drug.
Patients taking METOCLOPRAMIDE HYDROCHLORIDE who experience tardive dyskinesia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TARDIVE DYSKINESIA is moderately reported among METOCLOPRAMIDE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to tardive dyskinesia, the following adverse reactions have been reported for METOCLOPRAMIDE HYDROCHLORIDE:
The following drugs have also been linked to tardive dyskinesia in FDA adverse event reports:
TARDIVE DYSKINESIA has been reported as an adverse event in 16,216 FDA reports for METOCLOPRAMIDE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TARDIVE DYSKINESIA accounts for approximately 7.8% of all adverse event reports for METOCLOPRAMIDE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience tardive dyskinesia while taking METOCLOPRAMIDE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.